Benzimidazoles useful as inhibitors of protein kinases

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof;
• wherein
• Q is selected from the group consisting of
• R1 is H, C1-6aliphatic, or C3-8cycloaliphatic optionally substituted with 0-4 JR;
• each R2 is independently ZR, MR, (LR)-ZR or (XR)-MR;
• each JQ is independently ZQ, MQ, (LQ)-ZQ, or (XQ)-MQ;
• each LR, LQ, XR, and XQ is independently C1-6alkyl optionally interrupted with up to 2 occurrences of —NR—, —O—, —S—, —CO2—, —OC(O)—, —C(O)CO—, —C(O)—, —C(O)NR—, —C(═N—CN), —C(═N—OH), —NRCO—, —NRC(O)O—, —SO2NR—, —NRSO2—, —NRC(O)NR—, —OC(O)NR—, —NRSO2NR—, —SO—, or —SO2—;
• wherein
• each LR is independently and optionally substituted
• with 0-2 JLR;
• each LQ is independently and optionally substituted with 0-2 JLQ;
• each XR is independently and optionally substituted with 0-2 JXR;
• each XQ is independently and optionally substituted with 0-2 JXQ;
• each ZR and ZQ is independently H;
• C1-6 aliphatic;
• a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• wherein
• each ZR is independently and optionally substituted
• with 0-4 JZR;
• each ZQ is independently and optionally substituted
• with 0-4 JZQ;
• MQ is independently CN, CF3, NO2, OR, SR, or N(R)2;
• MR is independently halo, CN, CF3, NO2, OR, SR, or N(R)2;
• each JR is independently C1-6aliphatic, C1-6haloalkyl, halo, OH, C1-3alkoxy, NO2, or CN;
• each JLR, JLQ, JXR, JXQ, JZR, and JZQ is independently V, M, (LV)-V, (LM)-M, C1-6haloalkyl, halo, OH, C1-3alkoxy, NO2, or CN;
• each R is independently H, C1-6aliphatic, C6-10aryl, —(C1-6aliphatic)-(C6-10aryl), C3-8cycloaliphatic, —C(═O)(C1-6aliphatic), —C(═O)(C3-8cycloaliphatic), or —C(═O)O(C1-6aliphatic);
• wherein each R is independently and optionally substituted with 0-2 J;
• each LV and LM is independently C1-6alkyl optionally interrupted with up to 2 occurrences of —NR—, —O—, —S—, —CO2—, —OC(O)—, —C(O)CO—, —C(O)—, —C(O)NR—, —C(═N—CN), —C(═N—OH), —NRCO—, —NRC(O)O—, —SO2NR—, —NRSO2—, —NRC(O)NR—, —OC(O)NR—, —NRSO2NR—, —SO—, or —SO2—;
• wherein
• each LV is independently and optionally substituted with 0-2 JLV;
• each LM is independently and optionally substituted with 0-2 JLM;
• each V is independently H;
• C1-6 aliphatic;
• a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• wherein each V is independently and optionally substituted with 0-2 JV;
• each J, JLV, JLM, and JV is independently R′, C3-6cycloalkyl, C1-6haloalkyl, halo, NO2, CN, OH, OR′, SH, SR′, NH2, NHR′, N(R′)2, COH, COR′, CONH2, CONHR′, CON(R′)2, NHCOR′, NR′COR′, NHCONH2, NHCONHR′, NHCON(R′)2, NR′CONH2, NR′CONHR′, NR′CON(R′)2, SO2NH2, SO2NHR′, SO2N(R′)2, NHSO2R′, or NR′SO2R′;
• R′ is unsubstituted C1-6aliphatic;
• or two R′ groups, together with the atom to which they are bound, form an unsubstituted 3-8 membered saturated or partially saturated monocyclic ring having 0-1 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• each M is independently halo, CN, CF3, NO2, OH, O(C1-6alkyl), SH, S(C1-6alkyl), NH2, NH(C1-6alkyl), or N(C1-6alkyl)2;
• provided that
• when Q is
• and R2 is H, F, Cl, CH3, CF3, OCH3, or OCH2CH3 at the 5 or 6 position of the benzimidazole ring, then JQ is not —O—(C1-3aliphatic);
• when Q is
• then JQ is not
• optionally substituted with methyl.